<DOC>
	<DOCNO>NCT00005584</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Radiation therapy use high-energy x-rays damage cancer cell . Combining chemotherapy radiation therapy may kill cancer cell . It yet know combination chemotherapy regimen effective treat Hodgkin 's lymphoma . PURPOSE : Randomized phase III trial compare effectiveness different regimen combination chemotherapy without radiation therapy treat patient Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Radiation Therapy Treating Patients With Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare late toxicity 6 course epirubicin , bleomycin , vinblastine , prednisone ( EBVP ) follow involved-field radiotherapy ( IF-RT ) ( 36 Gy ) vs IF-RT ( 20 Gy ) , vs IF-RT ( close accrual 6/2002 ) patient supradiaphragmatic Hodgkin 's lymphoma , favorable prognosis , complete remission ( CR ) CR unconfirmed completion chemotherapy . ( Favorable prognosis group [ group 1 ] close accrual 4/28/04 . ) - Compare 6 course doxorubicin , bleomycin , vinblastine , dacarbazine ( ABVD ) vs 4 course ABVD vs 4 course cyclophosphamide , doxorubicin , vincristine , bleomycin , etoposide , procarbazine , prednisone ( BEACOPP ) follow IF-RT , respect overall survival late treatment-related toxicity , patient supradiaphragmatic Hodgkin 's lymphoma unfavorable prognosis . ( Unfavorable prognosis group [ group 2 ] close accrual 9/2002 . ) ( Favorable prognosis group [ group 1 ] close accrual 4/28/04 . ) - Maintain failure-free survival relapse-free survival rate reach previous EORTC study ( H5 H8 ) , reduction acute delay side effect treatment , particular severe late radiotherapy chemotherapy-related toxicity . - Compare quality life , overall survival , treatment quality control , duration treatment patient favorable ( closed accrual 4/28/04 ) unfavorable ( closed accrual 9/2002 ) prognosis treat regimen . - Determine efficacy conservative therapy comprise observation disease progression ( DP ) administration IF-RT time DP patient lymphocyte-predominant Hodgkin 's lymphoma , nodular subtype ( nodular paragranuloma ) . OUTLINE : This randomize , multicenter study . Patients classical Hodgkin 's lymphoma assign 1 2 randomized group . ( Group 2 [ unfavorable prognosis ] close accrual 9/2002 . ) ( Group 1 [ favorable prognosis ] close accrual 4/28/04 . ) Patients lymphocyte-predominant Hodgkin 's lymphoma assign nonrandomized group . Randomized group - Patients stratified prognosis ( favorable v unfavorable ) . Patients assign 1 2 treatment group base prognosis . ( Group 2 [ unfavorable prognosis ] close accrual 9/2002 . ) ( Group 1 [ favorable prognosis ] close accrual 4/28/04 . ) - Group 1 ( favorable prognosis ) ( close accrual 4/28/04 ) : Patients receive epirubicin IV 5 minute , bleomycin intramuscularly ( IM ) ( IV necessary ) , vinblastine IV day 1 oral prednisone day 1-5 . Treatment repeat every 3 week 6 course . Patients assign 1 3 involved-field radiotherapy ( IF-RT ) group base response chemotherapy : - Group A ( complete remission ( CR ) CR unconfirmed [ CRu ] ) Patients randomize 1 3 radiotherapy arm . ( Arm III close accrual 6/2002 . ) - Arm I ( 36 Gy ) : Patients undergo IF-RT 5 day week 3.5 week . - Arm II ( 20 Gy ) : Patients undergo IF-RT 5 day week 2 week . - Arm III ( close accrual 6/2002 ) : Patients undergo IF-RT . - Group B ( partial remission [ PR ] ) : Patients undergo IF-RT 5 day week 3.5 week boost radiotherapy . - Group C ( stable disease disease progression [ DP ] ) : Patients receive IF-RT take study . - Group 2 ( unfavorable prognosis ) ( close accrual 9/2002 ) : Patients randomize 1 3 treatment arm . - Arm I : Patients receive doxorubicin IV 5 minute , bleomycin IM ( IV necessary ) , vinblastine IV , dacarbazine IV 5-10 minute day 1 15 . Treatment repeat every 4 week 6 course . - Arm II : Patients receive chemotherapy arm I . Treatment repeat every 4 week 4 course . - Arm III : Patients receive cyclophosphamide IV doxorubicin IV 5 minute day 1 , vincristine IV bleomycin IM ( IV necessary ) day 8 , etoposide IV minimum 30 minute day 1-3 , oral procarbazine day 1-7 , oral prednisone day 1-14 . Treatment repeat every 3 week 4 course . Patients arm achieve CR CRu undergo IF-RT 5 day week 3 week . Patients achieve PR undergo IF-RT 5 day week 3.5 week boost radiotherapy . - Groups 1 2 ( group 2 close accrual 9/2002 ) ( group 1 close accrual 4/28/04 ) : IF-RT begin within 3-4 week completion last course chemotherapy . Nonrandomized group - Patients completely resect stage I disease undergo observation DP undergo IF-RT documentation DP . Patients stage II incompletely resect stage I disease undergo IF-RT immediately . Quality life assess start study therapy , immediately completion study , annually 10 year . Patients follow 2 , 4 , 6 , 9 , 12 month ; every 4 month 1 year ; every 6 month 3 year ; annually thereafter . PROJECTED ACCRUAL : A total 903 patient ( group 1 ) accrue study within 7.7 year . A total 723 patient ( group 2 ) accrue study within 3.8 year . ( Group 2 [ unfavorable prognosis ] close accrual 9/2002 . ) ( Group 1 [ favorable prognosis ] close accrual 4/28/04 . )</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Randomized group : Histologically prove previously untreated stage I II supradiaphragmatic Hodgkin 's lymphoma No prior stag laparotomy Favorable ( close accrual 4/28/04 ) unfavorable ( closed accrual 9/2002 ) prognosis Nonrandomized group : Histologically prove lymphocytepredominant Hodgkin 's lymphoma , nodular subtype ( nodular paragranuloma ) Stage I complete incomplete resection OR Stage II PATIENT CHARACTERISTICS : Age : 15 70 Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Cardiovascular : No severe cardiac disease would interfere normal life expectancy study treatment Pulmonary : No severe pulmonary disease would interfere normal life expectancy study treatment Other : No prior concurrent malignancy except basal cell skin cancer carcinoma situ cervix No severe neurologic metabolic disease would interfere normal life expectancy study treatment No psychologic , familial , socioeconomic , geographic circumstance would preclude proper stag compliance HIV negative Not pregnant Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy No prior biologic therapy malignancy Chemotherapy No prior chemotherapy malignancy Endocrine therapy No prior endocrine therapy malignancy Radiotherapy No prior radiotherapy malignancy Surgery No prior surgery malignancy</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>stage I adult Hodgkin lymphoma</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
	<keyword>adult lymphocyte predominant Hodgkin lymphoma</keyword>
</DOC>